Organisation paid for research Program year 2024 Source: CMS Open Payments

California Eye Specialists

Neither a doctor nor a teaching hospital

Research payments

$53,419

35 payments

Through program year 2024, California Eye Specialists is reported as receiving $53,419 in research payments, across 35 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $350 1
2023 Research $2,764 2
2022 Research $10,429 3
2021 Research $24,021 1
2020 Research $4,039 17
2019 Research $11,815 11

Breakdown

Who paid Research payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $25,545 4 payments
  2. Allergan Inc. $14,824 27 payments
  3. Ocular Therapeutix, Inc. $13,050 4 payments
Studies the money was for Research payments · program years 2019–2024
  1. A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $24,514 3 payments
  2. A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-Related MacUlar Degeneration $10,481 5 payments
  3. A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $5,000 1 payment
  4. A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $5,000 1 payment
  5. A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $4,343 22 payments
  6. A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $3,050 2 payments
  7. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $1,030 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record